Characterization of transplacental transfer of paroxetine in perfused human placenta

Development of a pharmacokinetic model to evaluate tapered dosing

Marie Nagai, Hisakazu Ohtani, Hiroki Satoh, Sayo Matsuoka, Satoko Hori, Tomoyuki Fujii, Yuji Taketani, Yasufumi Sawada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of this study was to determine whether a tapered dosage regimen of paroxetine in pregnant women might be useful to avoid withdrawal syndromes in neonates after delivery. We characterized the transplacental transfer of paroxetine in perfused human placenta, fitting a pharmacokinetic model to the results and applying the model and parameters to evaluate a tapered dosage regimen. Paroxetine was perfused from the maternal or fetal side of an isolated human placental preparation with various perfusion protocols, and paroxetine concentrations in the effluent and placental tissue were determined. The transplacental pharmacokinetic parameters of paroxetine were estimated by simultaneous fitting of a five-compartment transplacental pharmacokinetic model to the set of paroxetine concentration profiles. The developed model and parameters were used to simulate the maternal and fetal concentrations of paroxetine, and the results were compared with reported data. Paroxetine showed a larger distribution volume in placental tissue and a smaller transplacental transfer as compared with antipyrine, a passive diffusion marker. A five-compartment model could well describe the transplacental transfer of paroxetine and could well simulate the maternal and umbilical venous concentrations of paroxetine at delivery. Transplacental transfer kinetic parameters of paroxetine were estimated by fitting a pharmacokinetic model to perfusion study data. The model and parameters appeared to be suitable for simulation of paroxetine kinetics in fetus. The model was also applicable to design a dosage regimen to avoid an abrupt decrease of paroxetine concentration in fetal plasma.

Original languageEnglish
Pages (from-to)2124-2132
Number of pages9
JournalDrug Metabolism and Disposition
Volume41
Issue number12
DOIs
Publication statusPublished - 2013 Dec

Fingerprint

Paroxetine
Human Development
Placenta
Pharmacokinetics
Mothers
Perfusion
Umbilicus
Antipyrine
Pregnant Women

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Characterization of transplacental transfer of paroxetine in perfused human placenta : Development of a pharmacokinetic model to evaluate tapered dosing. / Nagai, Marie; Ohtani, Hisakazu; Satoh, Hiroki; Matsuoka, Sayo; Hori, Satoko; Fujii, Tomoyuki; Taketani, Yuji; Sawada, Yasufumi.

In: Drug Metabolism and Disposition, Vol. 41, No. 12, 12.2013, p. 2124-2132.

Research output: Contribution to journalArticle

Nagai, Marie ; Ohtani, Hisakazu ; Satoh, Hiroki ; Matsuoka, Sayo ; Hori, Satoko ; Fujii, Tomoyuki ; Taketani, Yuji ; Sawada, Yasufumi. / Characterization of transplacental transfer of paroxetine in perfused human placenta : Development of a pharmacokinetic model to evaluate tapered dosing. In: Drug Metabolism and Disposition. 2013 ; Vol. 41, No. 12. pp. 2124-2132.
@article{15724a46c99a4850a5ea9c7db0176010,
title = "Characterization of transplacental transfer of paroxetine in perfused human placenta: Development of a pharmacokinetic model to evaluate tapered dosing",
abstract = "The aim of this study was to determine whether a tapered dosage regimen of paroxetine in pregnant women might be useful to avoid withdrawal syndromes in neonates after delivery. We characterized the transplacental transfer of paroxetine in perfused human placenta, fitting a pharmacokinetic model to the results and applying the model and parameters to evaluate a tapered dosage regimen. Paroxetine was perfused from the maternal or fetal side of an isolated human placental preparation with various perfusion protocols, and paroxetine concentrations in the effluent and placental tissue were determined. The transplacental pharmacokinetic parameters of paroxetine were estimated by simultaneous fitting of a five-compartment transplacental pharmacokinetic model to the set of paroxetine concentration profiles. The developed model and parameters were used to simulate the maternal and fetal concentrations of paroxetine, and the results were compared with reported data. Paroxetine showed a larger distribution volume in placental tissue and a smaller transplacental transfer as compared with antipyrine, a passive diffusion marker. A five-compartment model could well describe the transplacental transfer of paroxetine and could well simulate the maternal and umbilical venous concentrations of paroxetine at delivery. Transplacental transfer kinetic parameters of paroxetine were estimated by fitting a pharmacokinetic model to perfusion study data. The model and parameters appeared to be suitable for simulation of paroxetine kinetics in fetus. The model was also applicable to design a dosage regimen to avoid an abrupt decrease of paroxetine concentration in fetal plasma.",
author = "Marie Nagai and Hisakazu Ohtani and Hiroki Satoh and Sayo Matsuoka and Satoko Hori and Tomoyuki Fujii and Yuji Taketani and Yasufumi Sawada",
year = "2013",
month = "12",
doi = "10.1124/dmd.113.052332",
language = "English",
volume = "41",
pages = "2124--2132",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "12",

}

TY - JOUR

T1 - Characterization of transplacental transfer of paroxetine in perfused human placenta

T2 - Development of a pharmacokinetic model to evaluate tapered dosing

AU - Nagai, Marie

AU - Ohtani, Hisakazu

AU - Satoh, Hiroki

AU - Matsuoka, Sayo

AU - Hori, Satoko

AU - Fujii, Tomoyuki

AU - Taketani, Yuji

AU - Sawada, Yasufumi

PY - 2013/12

Y1 - 2013/12

N2 - The aim of this study was to determine whether a tapered dosage regimen of paroxetine in pregnant women might be useful to avoid withdrawal syndromes in neonates after delivery. We characterized the transplacental transfer of paroxetine in perfused human placenta, fitting a pharmacokinetic model to the results and applying the model and parameters to evaluate a tapered dosage regimen. Paroxetine was perfused from the maternal or fetal side of an isolated human placental preparation with various perfusion protocols, and paroxetine concentrations in the effluent and placental tissue were determined. The transplacental pharmacokinetic parameters of paroxetine were estimated by simultaneous fitting of a five-compartment transplacental pharmacokinetic model to the set of paroxetine concentration profiles. The developed model and parameters were used to simulate the maternal and fetal concentrations of paroxetine, and the results were compared with reported data. Paroxetine showed a larger distribution volume in placental tissue and a smaller transplacental transfer as compared with antipyrine, a passive diffusion marker. A five-compartment model could well describe the transplacental transfer of paroxetine and could well simulate the maternal and umbilical venous concentrations of paroxetine at delivery. Transplacental transfer kinetic parameters of paroxetine were estimated by fitting a pharmacokinetic model to perfusion study data. The model and parameters appeared to be suitable for simulation of paroxetine kinetics in fetus. The model was also applicable to design a dosage regimen to avoid an abrupt decrease of paroxetine concentration in fetal plasma.

AB - The aim of this study was to determine whether a tapered dosage regimen of paroxetine in pregnant women might be useful to avoid withdrawal syndromes in neonates after delivery. We characterized the transplacental transfer of paroxetine in perfused human placenta, fitting a pharmacokinetic model to the results and applying the model and parameters to evaluate a tapered dosage regimen. Paroxetine was perfused from the maternal or fetal side of an isolated human placental preparation with various perfusion protocols, and paroxetine concentrations in the effluent and placental tissue were determined. The transplacental pharmacokinetic parameters of paroxetine were estimated by simultaneous fitting of a five-compartment transplacental pharmacokinetic model to the set of paroxetine concentration profiles. The developed model and parameters were used to simulate the maternal and fetal concentrations of paroxetine, and the results were compared with reported data. Paroxetine showed a larger distribution volume in placental tissue and a smaller transplacental transfer as compared with antipyrine, a passive diffusion marker. A five-compartment model could well describe the transplacental transfer of paroxetine and could well simulate the maternal and umbilical venous concentrations of paroxetine at delivery. Transplacental transfer kinetic parameters of paroxetine were estimated by fitting a pharmacokinetic model to perfusion study data. The model and parameters appeared to be suitable for simulation of paroxetine kinetics in fetus. The model was also applicable to design a dosage regimen to avoid an abrupt decrease of paroxetine concentration in fetal plasma.

UR - http://www.scopus.com/inward/record.url?scp=84888596865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888596865&partnerID=8YFLogxK

U2 - 10.1124/dmd.113.052332

DO - 10.1124/dmd.113.052332

M3 - Article

VL - 41

SP - 2124

EP - 2132

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 12

ER -